US Institute of Medicine panel says Congress should have more power to order post-market studies
This article was originally published in Clinica
Executive Summary
US Congress should give the FDA expanded authority to order post-market studies when issuing a pre-market notification or a 510(k), says a new report issued by a panel of experts convened by the Institute of Medicine (IoM).